These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 17725102)
1. Atypical thyroid nodules express both HBME-1 and Galectin-3, two phenotypic markers of papillary thyroid carcinoma. Coli A; Bigotti G; Parente P; Federico F; Castri F; Massi G J Exp Clin Cancer Res; 2007 Jun; 26(2):221-7. PubMed ID: 17725102 [TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules. Abd-El Raouf SM; Ibrahim TR Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma. Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217 [TBL] [Abstract][Full Text] [Related]
4. HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma. Nga ME; Lim GS; Soh CH; Kumarasinghe MP Diagn Cytopathol; 2008 Aug; 36(8):550-6. PubMed ID: 18618720 [TBL] [Abstract][Full Text] [Related]
5. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Rossi ED; Raffaelli M; Mule' A; Miraglia A; Lombardi CP; Vecchio FM; Fadda G Histopathology; 2006 Jun; 48(7):795-800. PubMed ID: 16722927 [TBL] [Abstract][Full Text] [Related]
6. Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. Inohara H; Segawa T; Miyauchi A; Yoshii T; Nakahara S; Raz A; Maeda M; Miyoshi E; Kinoshita N; Yoshida H; Furukawa M; Takenaka Y; Takamura Y; Ito Y; Taniguchi N Biochem Biophys Res Commun; 2008 Nov; 376(3):605-10. PubMed ID: 18809382 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of galectin-3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules. Aratake Y; Umeki K; Kiyoyama K; Hinoura Y; Sato S; Ohno A; Kuribayashi T; Hirai K; Nabeshima K; Kotani T Diagn Cytopathol; 2002 Jun; 26(6):366-72. PubMed ID: 12112826 [TBL] [Abstract][Full Text] [Related]
8. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Inohara H; Honjo Y; Yoshii T; Akahani S; Yoshida J; Hattori K; Okamoto S; Sawada T; Raz A; Kubo T Cancer; 1999 Jun; 85(11):2475-84. PubMed ID: 10357421 [TBL] [Abstract][Full Text] [Related]
9. Can cytomorphology differentiate between benign nodules and tumors arising in Graves' disease? Anderson SR; Mandel S; LiVolsi VA; Gupta PK; Baloch ZW Diagn Cytopathol; 2004 Jul; 31(1):64-7. PubMed ID: 15236269 [TBL] [Abstract][Full Text] [Related]
10. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. de Matos PS; Ferreira AP; de Oliveira Facuri F; Assumpção LV; Metze K; Ward LS Histopathology; 2005 Oct; 47(4):391-401. PubMed ID: 16178894 [TBL] [Abstract][Full Text] [Related]
11. Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC. Prasad ML; Huang Y; Pellegata NS; de la Chapelle A; Kloos RT Histopathology; 2004 Jul; 45(1):39-46. PubMed ID: 15228442 [TBL] [Abstract][Full Text] [Related]
12. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Weber KB; Shroyer KR; Heinz DE; Nawaz S; Said MS; Haugen BR Am J Clin Pathol; 2004 Oct; 122(4):524-31. PubMed ID: 15487449 [TBL] [Abstract][Full Text] [Related]
13. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions. Mataraci EA; Ozgüven BY; Kabukçuoglu F Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical study of papillary thyroid carcinoma and possible papillary thyroid carcinoma-related benign thyroid nodules. Mai KT; Ford JC; Yazdi HM; Perkins DG; Commons AS Pathol Res Pract; 2000; 196(8):533-40. PubMed ID: 10982016 [TBL] [Abstract][Full Text] [Related]
16. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin. Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548 [TBL] [Abstract][Full Text] [Related]
17. Ultrasound Risk Assessment Combined with Molecular Markers of Galectin-3, c-MET, HBME-1 and CK19 for Diagnosis of Malignant and Benign Thyroid Nodules. Han RL; Wang J; Zhang FJ; Zhao N; Gao BL Pathol Oncol Res; 2019 Jul; 25(3):1075-1081. PubMed ID: 30361909 [TBL] [Abstract][Full Text] [Related]
19. Immunocytochemical evaluation of thyroid neoplasms on thin-layer smears from fine-needle aspiration biopsies. Rossi ED; Raffaelli M; Minimo C; Mule A; Lombardi CP; Vecchio FM; Fadda G Cancer; 2005 Apr; 105(2):87-95. PubMed ID: 15742329 [TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. Park YJ; Kwak SH; Kim DC; Kim H; Choe G; Park DJ; Jang HC; Park SH; Cho BY; Park SY J Korean Med Sci; 2007 Aug; 22(4):621-8. PubMed ID: 17728499 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]